Brief: Orchard Therapeutics PLC Posts Qtrly Loss Per Share $0.35
28/05/2019 12:27
May 28 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS ANNOUNCES EXPANSION OF NEUROMETABOLIC
DISEASE PORTFOLIO AND REPORTS FIRST QUARTER 2019 FINANCIAL
RESULTS
* ORCHARD THERAPEUTICS PLC - CLINICAL TRIAL IN SANFILIPPO
SYNDROME
TYPE A (MPS-IIIA) NOW EXPECTED TO START LATER THIS YEAR
* ORCHARD THERAPEUTICS PLC - NEWLY SECURED $75 MILLION
CREDIT
FACILITY EXTENDS RUNWAY INTO 2021
* ORCHARD THERAPEUTICS PLC - ENDED Q1 OF 2019 WITH
APPROXIMATELY
$300M IN TOTAL CASH AND INVESTMENTS
* ORCHARD THERAPEUTICS PLC - NEWLY SECURED $75 MILLION
CREDIT
FACILITY EXTENDS RUNWAY INTO 2021
* ORCHARD THERAPEUTICS PLC - ANTICIPATED MAA SUBMISSION FOR
TREATMENT OF MLD BROUGHT FORWARD TO FIRST HALF OF 2020
* ORCHARD THERAPEUTICS PLC QTRLY LOSS PER SHARE $0.35
Source text for Eikon: ID:nGNX7NSX26
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln